IRF1 Luciferase Reporter Vector
- Known as:
- IRF1 Luciferase Reporter Vector
- Catalog number:
- LR0039
- Product Quantity:
- 10 ug
- Category:
- -
- Supplier:
- Panomics
- Gene target:
- IRF1 Luciferase Reporter Vector
Related genes to: IRF1 Luciferase Reporter Vector
- Gene:
- IRF1 NIH gene
- Name:
- interferon regulatory factor 1
- Previous symbol:
- -
- Synonyms:
- MAR
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1991-05-09
- Date modifiied:
- 2016-10-05
Related products to: IRF1 Luciferase Reporter Vector
Related articles to: IRF1 Luciferase Reporter Vector
- Preeclampsia (PE) is a pregnancy-specific disorder posing significant maternal-fetal risks, while interferon regulatory factor 1 (IRF1) is a transcriptional regulator associated with inflammatory responses. In this study, we aim to explore the pivotal correlation between PANoptosis and PE pathogenesis, as well as the regulatory role of IRF1 in PE progression. - Source: PubMed
Publication date: 2026/04/25
Wang ZhichaoCheng LongLi GuanghuiKong LiliCheng Huiyan - A lack of effective antitumor T-cell immunity often drives immune evasion and immunotherapy resistance. Here, we demonstrated that tumor-intrinsic ARHGEF3 reprogrammed the tumor microenvironment into a T-cell-inflamed state, resulting in potent antitumor effects. Mechanistically, ARHGEF3 functioned as a guanine nucleotide exchange factor that activated the RHOA-ROCK-PTEN cascade and inhibited AKT signaling. This inhibition upregulated IRF1-dependent chemokines CXCL10 and CXCL11 to drive T-cell infiltration, while suppressing FASN-mediated fatty acid synthesis to limit myeloid cell-mediated immunosuppression. The dual effects elicited robust T-cell immunity and overcame tumor resistance to immunotherapy. In human tumors, ARHGEF3 expression correlated positively with T-cell-inflamed signatures, improved clinical outcomes, and responsiveness to immunotherapy. Collectively, these findings identify ARHGEF3 as a key modulator linking chemokine signaling with lipid availability to shape T-cell immunity, offering a promising therapeutic strategy to overcome immunotherapy resistance. - Source: PubMed
Publication date: 2026/04/23
Li YueWang LanZhang ZihaoQian ChunmeiLi NingHuang WeiBa QianLiu XiaojianSun Mayu - Immunotherapy has emerged as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC), but over half of patients fail to benefit, largely due to tumor heterogeneity and a complex tumor microenvironment. Here, we demonstrate that fibrinogen-like protein 1 (FGL1), a recently identified immune checkpoint ligand, is targeted by tripartite motif-containing protein 21 (TRIM21) for proteasomal degradation, thereby enhancing the anti-tumor activity of cytotoxic T lymphocytes (CTLs). We further show that interferon regulatory factor 1 (IRF1) regulates TRIM21 transcription. Artemisinin upregulates the IRF1-TRIM21 axis, promoting FGL1 degradation. In high FGL1 expressed tumors, artemisinin in combination with anti-programmed cell death protein 1 (anti-PD-1) therapy enhances immunotherapeutic efficacy. Clinically, an elevated FGL1/TRIM21 protein ratio is associated with poor prognosis in NSCLC. Collectively, these findings elucidate a post-translational regulatory mechanism of FGL1 in tumor progression and support the development of a rational combination immunotherapy strategy for NSCLC treatment. - Source: PubMed
Publication date: 2026/04/22
Zhang YuchenZhou PingjingGuo YifanZhang HongyuZhao GuangyinYin JunGe DiLiu RonghuaGu JieZhang Chunyi - Maxim (DrT) is a well-known traditional medicinal and edible plant with hepatoprotective effects. In this study, crude polysaccharides of DrT (DrTPs) were obtained using the water extraction-ethanol precipitation method. Autoimmune hepatitis (AIH) models of both mice and ALM12 cells were produced by ConA. The serum liver function indexes (AST and ALT) were examined by ELISA, and liver tissue pathological changes were observed by HE staining. The hepatoprotective mechanism of DrTP80 was explored by RNA sequencing and verified by detecting the protein expressions using Western blot. As a result, DrTP80 could significantly reduce AST and ALT levels in the injured liver and ALM12 cells. DrTP80 also obviously improved the hepatopathological changes in liver tissue induced by ConA. Furthermore, RNA sequencing detected significant differences in gene expression, and the functions of differential genes were focused on TNF and IL-17 signaling pathways. Based on these two signaling pathways, 13 differentially expressed genes (Vcam1, Atf6b, Akt1, Irf1, Map2k3, Lcn2, Hsp90ab1, Anapc5, Traf4, Fosl1, Jun, Cxcl5, Nfκbia) among NC, CRC, and FP groups were screened and verified by Western blot. In conclusion, our results demonstrated that DrTP80 can alleviate immune liver damage induced by ConA, and its hepatoprotective mechanism may be related to regulating TNF and IL-17 signaling pathways. Our findings indicated that DrTP80 could be exploited as a healthy food supplement for the treatment of immune liver injury. - Source: PubMed
Publication date: 2026/03/24
Guo MinWei SaixueCheng BiaobiaoLi Xiaodong - Psoriasis, a chronic inflammatory skin disease affecting 2-3% of the global population, is driven by dysregulated immune responses. Despite advancements in biologic therapies, treatment challenges persist due to high recurrence rates. This study aimed to identify immune-related hub genes and elucidate their clinical implications in psoriasis pathogenesis and therapy. - Source: PubMed
Publication date: 2026/04/20
Sun YuzhenZhou ZiguangMao YuLiu NiuLi YanfengFang Weiyuan